Madrigal Pharmaceuticals Announces Exclusive Global License Agreement With Arrowhead Pharmaceuticals For ARO-PNPLA3
Benzinga Newsdesk 6 months ago
BiotechNewsGeneral
Company advances its leadership in MASH with clinical-stage, genetically targeted siRNA asset from Arrowhead PharmaceuticalsPrecision approach targets patients who have a mutation in the PNPLA3 gene, which is highly
- Company advances its leadership in MASH with clinical-stage, genetically targeted siRNA asset from Arrowhead Pharmaceuticals
- Precision approach targets patients who have a mutation in the PNPLA3 gene, which is highly prevalent among Hispanic patients with MASH
- Phase 1 data published in The New England Journal of Medicine demonstrated a 46% liver fat reduction in homozygous patients and a well-tolerated safety profile
- Madrigal's pipeline includes more than 10 programs at multiple stages of development, anchored by Rezdiffra® (resmetirom) as the foundational treatment